ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
US |
|
Al-Dawaa Medical Services Co
SAU:4163
|
SA |
|
BP PLC
LSE:BP
|
UK |
|
T
|
Tropical Canning Thailand PCL
SET:TC
|
TH |
|
L
|
Link Real Estate Investment Trust
OTC:LKREF
|
HK |
|
Prairiesky Royalty Ltd
TSX:PSK
|
CA |
|
Supreme Holdings & Hospitality (India) Ltd
BSE:530677
|
IN |
|
Northamber PLC
LSE:NAR
|
UK |
|
E
|
East West Banking Corp
XPHS:EW
|
PH |
|
Provident Bancorp Inc (Maryland)
NASDAQ:PVBC
|
US |
|
D
|
Dharmaj Crop Guard Ltd
NSE:DHARMAJ
|
IN |
|
Surge Energy Inc
TSX:SGY
|
CA |
Wall Street
Price Targets
ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ACAD
is 32.37 USD
with a low forecast of 17.17 USD and a high forecast of 47.25 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ACAD's stock price target?
Price Target
32.37
USD
According to Wall Street analysts, the average 1-year price target for
ACAD
is 32.37 USD
with a low forecast of 17.17 USD and a high forecast of 47.25 USD.
What is ACADIA Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
14%
The
compound annual growth rate
of ACADIA Pharmaceuticals Inc's revenue for the next 3 years is
14%.
What is ACADIA Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
41%
The
compound annual growth rate
of ACADIA Pharmaceuticals Inc's operating income for the next 3 years is
41%.
What is ACADIA Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
-8%
The
compound annual growth rate
of ACADIA Pharmaceuticals Inc's net income for the next 3 years is
-8%.
